Andre Schrattenholz

Person

Mainz, DE

People

Patents Grantslast 30 patents

Information Patent Grant
Method of effecting neuroprotection using soluble neuregulin isoforms
- Patent number 10,813,978
- Issue date Oct 27, 2020
- MIND-NRG SARL
- André Schrattenholz
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Method of effecting neuroprotection using soluble Neuregulin isoforms
- Patent number 10,350,269
- Issue date Jul 16, 2019
- MIND-NRG SARL
- André Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Use of neuregulin-β as an indicator and/or target
- Patent number 8,546,086
- Issue date Oct 1, 2013
- Mind-NRG SA
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Muscarinic antagonists with parp and sir modulating activity as cyt...
- Patent number 8,466,144
- Issue date Jun 18, 2013
- Proteosys AG
- André Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Annexin A3 for cancer diagnosis
- Patent number 8,409,812
- Issue date Apr 2, 2013
- ProteoSys AG
- Michael Cahill
- G01 - MEASURING TESTING
Information Patent Grant
Autoimmune regulation of prostate cancer by annexin A3
- Patent number 8,377,648
- Issue date Feb 19, 2013
- Proteosys AG
- Andre Schrattenholz
- G01 - MEASURING TESTING
Information Patent Grant
Muscarinic antagonists with PARP and SIR modulating activity as age...
- Patent number 8,039,464
- Issue date Oct 18, 2011
- Proteosys AG
- André Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Monoclonal anti-annexin A3 antibodies for the detection of prostate...
- Patent number 8,012,697
- Issue date Sep 6, 2011
- Proteosys AG
- Andre Schrattenholz
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Use of finasteride, dutasteride and related compounds for the preve...
- Patent number 7,998,970
- Issue date Aug 16, 2011
- Proteosys AG
- Vukic Soskic
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Neuregulin-β isoform
- Patent number 7,919,582
- Issue date Apr 5, 2011
- Mind-Ngr SA
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Neuregulin-β isoforms associated with neuronal processes
- Patent number 7,824,923
- Issue date Nov 2, 2010
- Proteosys AG
- André Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Use of substances for treating tumors
- Patent number 7,759,068
- Issue date Jul 20, 2010
- Proteosys AG
- Michael Cahill
- G01 - MEASURING TESTING
Information Patent Grant
Annexin A3 for prostate cancer diagnosis
- Patent number 7,732,148
- Issue date Jun 8, 2010
- ProteoSys AG
- Michael Cahill
- G01 - MEASURING TESTING
Information Patent Grant
Use of neuregulin-β as an indicator and/or target
- Patent number 7,538,197
- Issue date May 26, 2009
- Proteosys AG
- André Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Patents Applicationslast 30 patents

Information Patent Application
METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS
- Publication number 20210128687
- Publication date May 6, 2021
- MIND-NRG SARL
- André SCHRATTENHOLZ
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS
- Publication number 20210077579
- Publication date Mar 18, 2021
- MIND-NRG SARL
- André SCHRATTENHOLZ
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS
- Publication number 20190307848
- Publication date Oct 10, 2019
- MIND-NRG SARL
- André SCHRATTENHOLZ
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS
- Publication number 20170035849
- Publication date Feb 9, 2017
- MIND-NRG SARL
- André Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ACTIVE SOLUBLE POST-TRANSLATIONALLY MODIFIED NEUREGULIN ISOFORMS
- Publication number 20150239948
- Publication date Aug 27, 2015
- MIND-NRG SA
- ANDRÉ SCHRATTENHOLZ
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
NEUREGULIN ISOFORMS, NEUREGULIN POLYPEPTIDES AND USES THEREOF
- Publication number 20150080302
- Publication date Mar 19, 2015
- MIND-NRG SA
- Thierry Baussant
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
METHOD OF INHIBITING DOPAMINERGIC CELL DEATH
- Publication number 20140323408
- Publication date Oct 30, 2014
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PIRENZEPINE AS AN AGENT IN CANCER TREATMENT
- Publication number 20140271922
- Publication date Sep 18, 2014
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS
- Publication number 20140243269
- Publication date Aug 28, 2014
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PHARMACEUTICAL COMPOSITION CONTAINING NEUREGULIN ISOFORMS
- Publication number 20140243270
- Publication date Aug 28, 2014
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
NEUREGULIN ISOFORMS,NEUREGULIN POLYPEPTIDES AND USES THEREOF
- Publication number 20130072437
- Publication date Mar 21, 2013
- MIND-NRG SA
- Thierry Baussant
- C12 - BIOCHEMISTRY BEER SPIRITS WINE VINEGAR MICROBIOLOGY ENZYMOLOGY MUTATION...
Information Patent Application
PIRENZEPINE AS AN AGENT IN CANCER TREATMENT
- Publication number 20110294791
- Publication date Dec 1, 2011
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PIRENZEPINE AS OTOPROTECTIVE AGENT
- Publication number 20110263574
- Publication date Oct 27, 2011
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USE OF NEUREGULIN-ß AS AN INDICATOR AND/OR TARGET
- Publication number 20110244507
- Publication date Oct 6, 2011
- MIND-NRG SA
- ANDRÉ SCHRATTENHOLZ
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PROTEIN BIOMARKERS FOR IN VITRO TESTING OF DEVELOPMENTAL TOXICITY A...
- Publication number 20110143366
- Publication date Jun 16, 2011
- PROTEOSYS AG
- Andre Schrattenholz
- G01 - MEASURING TESTING
Information Patent Application
BREAST CANCER PROTEINS
- Publication number 20110098234
- Publication date Apr 28, 2011
- Michael Cahill
- G01 - MEASURING TESTING
Information Patent Application
ANNEXIN FOR CANCER RISK ASSESSMENT
- Publication number 20100267051
- Publication date Oct 21, 2010
- ProteoSys AG, a corporation of Germany
- Michael Cahill
- G01 - MEASURING TESTING
Information Patent Application
ACTIVE SOLUBLE POST-TRANSLATIONALLY MODIFIED NEUREGULIN ISOFORMS
- Publication number 20100256066
- Publication date Oct 7, 2010
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
PIRENZEPINE AND DERIVATIVES THEREOF AS ANTI-AMYLOID AGENTS
- Publication number 20100247688
- Publication date Sep 30, 2010
- Andrea Pfeifer
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Monoclonal Anti-Annexin A3 Antibodies for the Detection of Prostate...
- Publication number 20100233160
- Publication date Sep 16, 2010
- PROTEOSYS AG
- Andre Schrattenholz
- C07 - ORGANIC CHEMISTRY
Information Patent Application
AUTOIMMUNE REGULATION OF PROSTATE CANCER BY ANNEXIN A3
- Publication number 20100129834
- Publication date May 27, 2010
- PROTEOSYS AG
- Andre Schrattenholz
- G01 - MEASURING TESTING
Information Patent Application
USE OF NEUREGULIN-BETA AS AN INDICATOR AND/OR TARGET
- Publication number 20090286273
- Publication date Nov 19, 2009
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVE...
- Publication number 20090170889
- Publication date Jul 2, 2009
- PROTEOSYS AG
- Vukic Soskic
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Phosphorylated or Non-Phosphorylated MPR as Diagnostic Marker or Th...
- Publication number 20090061461
- Publication date Mar 5, 2009
- Michael Cahill
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Annexin for Cancer Risk Assessment
- Publication number 20080200385
- Publication date Aug 21, 2008
- ProteoSys AG, a corporation of Germany,
- Michael Cahill
- G01 - MEASURING TESTING
Information Patent Application
Enrichment of Enzymatic Cleavage Products
- Publication number 20070298448
- Publication date Dec 27, 2007
- PROTEOSYS AG
- Vukic Soskic
- Y02 - TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMA...
Information Patent Application
Muscarinic Antagonists With Parp and Sir Modulating Activity as Cyt...
- Publication number 20070265251
- Publication date Nov 15, 2007
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Muscarinic Antagonists With Parp and Sir Modulating Activity as Age...
- Publication number 20070207998
- Publication date Sep 6, 2007
- PROTEOSYS AG
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Use of substances for treating tumors
- Publication number 20050130876
- Publication date Jun 16, 2005
- Michael Cahill
- G01 - MEASURING TESTING
Information Patent Application
Nueregulin-beta isoforms associated with neuronal processes
- Publication number 20040197822
- Publication date Oct 7, 2004
- Andre Schrattenholz
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Andre Schrattenholz

Person

Patents Grantslast 30 patents

Method of effecting neuroprotection using soluble neuregulin isoforms

Method of effecting neuroprotection using soluble Neuregulin isoforms

Use of neuregulin-β as an indicator and/or target

Muscarinic antagonists with parp and sir modulating activity as cyt...

Annexin A3 for cancer diagnosis

Autoimmune regulation of prostate cancer by annexin A3

Muscarinic antagonists with PARP and SIR modulating activity as age...

Monoclonal anti-annexin A3 antibodies for the detection of prostate...

Use of finasteride, dutasteride and related compounds for the preve...

Neuregulin-β isoform

Neuregulin-β isoforms associated with neuronal processes

Use of substances for treating tumors

Annexin A3 for prostate cancer diagnosis

Use of neuregulin-β as an indicator and/or target

Patents Applicationslast 30 patents

METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS

METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS

METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS

METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS

ACTIVE SOLUBLE POST-TRANSLATIONALLY MODIFIED NEUREGULIN ISOFORMS

NEUREGULIN ISOFORMS, NEUREGULIN POLYPEPTIDES AND USES THEREOF

METHOD OF INHIBITING DOPAMINERGIC CELL DEATH

PIRENZEPINE AS AN AGENT IN CANCER TREATMENT

METHOD OF EFFECTING NEUROPROTECTION USING SOLUBLE NEUREGULIN ISOFORMS

PHARMACEUTICAL COMPOSITION CONTAINING NEUREGULIN ISOFORMS

NEUREGULIN ISOFORMS,NEUREGULIN POLYPEPTIDES AND USES THEREOF

PIRENZEPINE AS AN AGENT IN CANCER TREATMENT

PIRENZEPINE AS OTOPROTECTIVE AGENT

USE OF NEUREGULIN-ß AS AN INDICATOR AND/OR TARGET

PROTEIN BIOMARKERS FOR IN VITRO TESTING OF DEVELOPMENTAL TOXICITY A...

BREAST CANCER PROTEINS

ANNEXIN FOR CANCER RISK ASSESSMENT

ACTIVE SOLUBLE POST-TRANSLATIONALLY MODIFIED NEUREGULIN ISOFORMS

PIRENZEPINE AND DERIVATIVES THEREOF AS ANTI-AMYLOID AGENTS

Monoclonal Anti-Annexin A3 Antibodies for the Detection of Prostate...

AUTOIMMUNE REGULATION OF PROSTATE CANCER BY ANNEXIN A3

USE OF NEUREGULIN-BETA AS AN INDICATOR AND/OR TARGET

USE OF FINASTERIDE, DUTASTERIDE AND RELATED COMPOUNDS FOR THE PREVE...

Phosphorylated or Non-Phosphorylated MPR as Diagnostic Marker or Th...

Annexin for Cancer Risk Assessment

Enrichment of Enzymatic Cleavage Products

Muscarinic Antagonists With Parp and Sir Modulating Activity as Cyt...

Muscarinic Antagonists With Parp and Sir Modulating Activity as Age...

Use of substances for treating tumors

Nueregulin-beta isoforms associated with neuronal processes